Originally published as JCO Early Release 10.1200/JCO.2004.02.110 on July 12 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aljada, I. S. Articles by Tan, D. Search for Related Content PubMed PubMed Citation Articles by Aljada, I. S. Articles by Tan, D. Related Articles Related Editorial Social Bookmarking                            What's this?

Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non–Small-Cell Lung Cancer

Roswell Park Cancer Institute, State University of New York, Buffalo, NY; University of Pennsylvania, Philadelphia, PA; H. Lee Moffitt Cancer Center, Tampa, FL; and Tufts New England Medical Center, Boston, MA

Address reprint requests to Dongfeng Tan, MD, Departments of Pathology and Cancer Genetics, Roswell Park Cancer Institute, State University of New York, Buffalo, Elm and Carlton Sts, Buffalo, NY 14263; e-mail: dongfeng.tan{at}roswellpark.org

PURPOSE: Tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring inhibitors of matrix metalloproteinases (MMPs). It has been shown that TIMP-1 may be a multifunctional protein. Little is known about the role of TIMP-1 in progression and metastasis of human lung cancer (tumor inhibiting or tumor promoting), although studies using a variety of techniques have analyzed the expression of TIMP-1 mRNA and/or protein in human cancers.

PATIENTS AND METHODS: We examined the expression of TIMP-1 protein by immunohistochemistry in patients (n = 160) with primary respectable (stage I to IIIA) non–small-cell lung cancer (NSCLC).

RESULTS: Twenty-seven percent of the tumors (43 of 160) demonstrated elevated expression of this protein. We demonstrate that overexpression of TIMP-1 protein is associated with an adverse outcome. In addition, disease stage, patient's age, and performance status were all significantly related to survival. In multivariate analyses, patients with high TIMP-1 expression had a 90% increased risk of death when compared with those with low expression (relative risk, 1.92; 95% CI, 1.19 to 3.09; P = .008). TIMP-1 expression did not correlate with expression of MMP-2 and MMP-9.

CONCLUSION: These results suggest that TIMP-1, independent of its inhibiting activity of MMPs, may have other function(s) critical for NSCLCs. The significance of our results is two-fold. The adverse outcome in patients with overexpression of TIMP-1 indicates its potential prognostic value in NSCLC. Thus, TIMP-1 overexpression may serve to help identify patients with particularly aggressive disease for adjuvant treatments. In addition, the TIMP-1 molecule may represent a novel therapeutic target for treatment of some NSCLCs.

Supported in part by a grant from the Roswell Park Cancer Institute and by shared resources of the Roswell Park Cancer Institute core grant NIH P30 CA016056-27.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Assessing Prognosis in Non–Small-Cell Lung Cancer: Avenues to a More Complete Picture?
  Steven M. Dubinett, David Elashoff, and Matthew Meyerson
  JCO 2004 22: 3209-3211 [Full Text]

This article has been cited by other articles:

				H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein Clin. Cancer Res., May 1, 2005; 11(9): 3257 - 3264. [Abstract] [Full Text] [PDF]

				N. B. Leighl, L. Paz-Ares, J.-Y. Douillard, C. Peschel, A. Arnold, A. Depierre, A. Santoro, D. C. Betticher, U. Gatzemeier, J. Jassem, et al. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J. Clin. Oncol., April 20, 2005; 23(12): 2831 - 2839. [Abstract] [Full Text] [PDF]

				S. M. Dubinett, D. Elashoff, and M. Meyerson Assessing Prognosis in Non-Small-Cell Lung Cancer: Avenues to a More Complete Picture? J. Clin. Oncol., August 15, 2004; 22(16): 3209 - 3211. [Full Text] [PDF]